Search Blog
Categories
December 2018
M T W T F S S
« Nov    
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Tags

Hafren Dyfrdwy Delivers Further Resilience With Emergency Water Supply Contract From Water Direct

By Water Direct

EARLS COLNE, ESSEX / ACCESSWIRE / December 16, 2018 / Water Direct has announced that Hafren Dyfrdwy has become the latest water company to invest in its Nationwide Bottled Water Bank. The move secures emergency bottled water supplies to satisfy Hafren Dyfrdwy’s SEMD requirement in Powys and in the area around Wrexham, in the event of loss of water supply.

Hafren Dyfrdwy, which means Severn Dee, the two rivers running through Wales, became the new water company for all former Severn Trent and Dee Valley Water customers in Wales in July 2018. Its dedication to customer excellence includes 24/7 customer service and a dedicated business support team. Additionally, Hafren Dyfrdwy has created a dedicated Care and Assistance team to safeguard its most vulnerable customers.

By joining Water Direct’s Nationwide Bottled Water Bank, Hafren Dyfrdwy has assured the shortest available response time for its customers in the event of a water supply interruption. The service provides a large nationwide supply of emergency bottled water, stored at strategic locations across the UK for fast response deployment via its dedicated fleet. The scheme allocates pre-agreed stocks of two-litre bottles that can be delivered to pre-arranged sites or direct to the doorstep for vulnerable customers.

Rob Allan, Senior Wholesale Relationship Manager at Water Direct commented, “Hafren Dyfrdwy has a clear investment in the welfare of its customers in creating and delivering support and communications. Partnering with Water Direct to ensure a fast response and access to alternative water supply during an incident enhances Hafren Dyfrdwy’s commitment to delivering excellence and exceeding customer service requirements.”

Rhys Addison, from Hafren Dyfrdwy, added: “Water Direct’s services are really important to us. Their commitment to us, and the continual development of their offering to suit our needs, are what really sets them apart. We’re really confident in this partnership and how it helps us meet our objectives.”

About Us

Company information:

With nationwide coverage and 24/7 service, Water Direct provides planned and emergency temporary water wherever and whenever it’s needed.

Water Direct’s services range from supporting utility companies experiencing an interruption due to a burst main or contamination, to building sites in need of water for welfare or site processes, or private individuals in need of a swimming pool fill.

The company has been running for 22 years and in the last year alone, Water Direct delivered around 100 million litres of water to its customers.

Water Direct was one of the UK’s earliest adopters of contingency planning for water loss and achieved ISO 22301:2012 for resilience as a business.

Water Direct’s work has been recognized in 2018 through a number of awards including winning the CIR ‘Disaster Recovery as a Service’ Award and the Future Water Association ‘People’ Award along with finalists in the Water Industry ‘Contractor of the Year’ Award, Countywide Business Awards ‘Growing Business of the Year’, Essex Business Excellence Awards ‘Excellence in Innovation & Technology’ and Utility Week, ‘Utility Partner of the Year’.

www.water-direct.co.uk

Contacts

Liv Morris Victor Building, Unit 19, Earls Colne Business Park, Earls Colne, Colchester, Essex, CO6 2NS
Marketing Manager
Mobile: 0345 345 1725
livmorris@water-direct.co.uk
www.water-direct.co.uk

Links

www.water-direct.co.uk

SOURCE: Water Direct

ReleaseID: 530658

Medicenna Announces Pricing of Marketed Offering of Units

Toronto, Ontario and Houston, Texas–(Newsfile Corp. – December 14, 2018) – Medicenna Therapeutics Corp. (“Medicenna” or the “Company“) (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce today that it has priced its previously announced marketed offering (the “Offering“) of units of the Company (“Units“). The Company intends to issue a minimum of 4,000,000 Units and a maximum of 6,000,000 Units at a price of CDN$1.00 per Unit for minimum gross proceeds of CDN$4,000,000 and maximum gross proceeds of CDN$6,000,000. Each Unit is comprised of one common share of the Company (a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a “Warrant“). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of CDN$1.20 per Common Share for a period of 60 months following the closing of the Offering.

The Offering will be undertaken on a best efforts basis pursuant to the terms and conditions of an agency agreement (the “Agency Agreement“) entered into between Bloom Burton Securities Inc. (the “Lead Agent“), Mackie Research Capital Corporation and Richardson GMP Limited (together with the Lead Agent, the “Agents“) and the Company. In connection with the Offering, the Agents will be paid a cash commission equal to 7.0% of the aggregate gross proceeds of the Offering and will be issued broker warrants exercisable to acquire such number of Common Shares as is equal to 7.0% of the aggregate number of Units sold pursuant to the Offering.

A preliminary short form prospectus in respect of the Offering dated November 8, 2018 (the “Preliminary Prospectus“) has been filed in each of the provinces of British Columbia, Alberta and Ontario. A copy of the Preliminary Prospectus is available under the Company’s profile at www.sedar.com.

The net proceeds of the Offering will be used to fund continued clinical development of the Company’s on-going Phase 2b clinical trials of MDNA55 in recurrent glioblastoma (rGBM) and the Company’s development of IL-2 Superkines, as well as for working capital and other general corporate purposes. Further details are disclosed in the Preliminary Prospectus.

The Offering is subject to the satisfaction of certain customary closing conditions, including, but not limited to, the approval of the Toronto Stock Exchange.

This news release is not an offer of the Units for sale in the United States. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Units, in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such province, state or jurisdiction.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna’s wholly owned subsidiary, Houston-based Medicenna Biopharma Inc., is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a significant non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna’s lead IL4-EC, MDNA55, is enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements with respect to the use of the net proceeds of the Offering and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the Preliminary Prospectus, the annual information form of the Company dated June 26, 2018 and in other filings made by the Company with the applicable securities regulators from time to time.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.

Medicenna:

Fahar Merchant, President and Chief Executive Officer, 604-671-6673, fmerchant@medicenna.com;

Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com.

MZ Group:

Mike Cole, 1-949-259-4988, mike.cole@mzgroup.us.

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES.

Abattis Bioceuticals Corp., A Fully Integrated Medical Marijuana Company, CEO Clip Video

Vancouver, British Columbia–(Newsfile Corp. – December 14, 2018) – CEO & President of Abattis Bioceuticals Corp., Robert Abenante, speaks on the medical marijuana company’s many facets including: a vape line, extraction and laboratory services.

If you cannot view the video above, please visit:
https://www.b-tv.com/abattis-bioceuticals-ceo-clip-90sec/

Abattis Bioceuticals Corp. is being featured on BNN Bloomberg on Dec. 15 – Dec. 16, 2018, throughout the day and evenings.

Abattis Bioceuticals (CSE: ATT) (OCTQB: ATTBF)

abattis.com

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles broadcast on national TV and online via 15 top financial sites including: Thomson Reuters, Bloomberg, Yahoo! Finance and Stockhouse.com.

BTV – Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

Peekaboo Beans, A Children’s Clothing Company That’s Solving Problems, CEO Clip Video

Vancouver, British Columbia–(Newsfile Corp. – December 14, 2018) – CEO & Founder of Peekaboo Beans, Traci Costa, speaks on how her company is helping the world.

If you cannot view the video above, please visit:
https://www.b-tv.com/peekaboo-beans-ceo-clip-90sec/

Peekaboo Beans is being featured on BNN Bloomberg on Dec. 15 – Dec. 16, 2018, throughout the day and evenings.

Peekaboo Beans (CSE: BEAN)

shopca.peekaboobeans.com

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles broadcast on national TV and online via 15 top financial sites including: Thomson Reuters, Bloomberg, Yahoo! Finance and Stockhouse.com.

BTV – Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

Tidal Royalty Corp. Terminates Letter of Intent with CannaRoyalty Corp.

Toronto, Ontario–(Newsfile Corp. – December 14, 2018) – Tidal Royalty Corp. (CSE: RLTY.U) (“Tidal Royalty“) announces that effective immediately it has terminated the letter of intent (“LOI“) with CannaRoyalty Corp. announced August 27, 2018 with respect to the acquisition of a royalty entitlement and equity interest in Alternative Medical Enterprises, LLC. Tidal Royalty has decided not to proceed with the transaction contemplated by the LOI following completion of its due diligence investigation.

About Tidal Royalty

Tidal Royalty provides royalty financing to the U.S. regulated cannabis industry. Led by an executive team with extensive industry experience in Canada and the U.S., Tidal Royalty provides operators with the funding they need to grow their business. Operators benefit from non-dilutive capital and investors get top-line access to a diversified portfolio of companies that will form the future of this transformative industry.

For further information, please contact:

Tidal Royalty Corp.
Terry Taouss, President
Email: terry@tidalroyalty.com

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Mainstream Minerals Announces Private Placement

Toronto, Ontario–(Newsfile Corp. – December 14, 2018) – Mainstream Minerals Corporation (the “Company“) announces that it intends to complete a private placement for aggregate gross proceeds of $500,000 through the issuance of 50,000,000 common shares (“Common Shares“) of the Company at a price of $0.01 per Common Share (the “Offering“).

All Common Shares issued in connection with the Offering are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

For further information, please contact:

Lisa McCormack
President & Chief Executive Officer
Tel: 416-361-2515
Email: lmccormack@irwinlowy.com

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

By Enovachem Pharmaceuticals

TORRANCE, CA / ACCESSWIRE / December 14, 2018 / Asclemed USA Inc is voluntarily recalling 20 lots of Dyural-40 and 61 lots of Dyural-80, to the user level. The products include recalled Sodium Chloride, USP, 0.9% manufactured by Fresenius Kabi, which has been recalled due to product labeling incorrectly stating stoppers do not contain latex.

For the population most at risk, those with a severe allergic reaction to latex, there is probability of an anaphylactic reaction, and this could result in hospitalization or death. To date, Asclemed USA Inc has not received any reports of adverse events related to this recall.

The products are Dyural-40 convenience kits packaged in plastic trays and Dyural-80 convenience kits packaged in plastic trays, containing Sodium Chloride, USP, 0.9% by Fresenius Kabi.

The affected Dyural-40 lots include the following:

The affected Dyural-80 lots include the following:

The products can be identified by lot and expiration stamped on the front of each convenience kit. Product was distributed Nationwide to distributors and physicians.

Asclemed USA Inc is notifying its distributors and customers by email and is arranging for return of all recalled products. Distributors and physicians that have Dyural-40 or Dyural-80 which is being recalled should stop using them and return to place of purchase.

Consumers with questions regarding this recall can contact Asclemed USA Inc by calling (310) 320-0100 ext. 120 Monday through Friday from 7:30am to 4:00pm PST or emailing christinah@enovachem.us.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact:

Christina Hopson
(310) 320-0100 ext. 120

SOURCE: Enovachem Pharmaceuticals

ReleaseID: 530603

Peekaboo Beans Announces $500,000 Non-brokered Private Placement

Vancouver, British Columbia–(Newsfile Corp. – December 14, 2018) – Peekaboo Beans Inc. (CSE: BEAN) (OTCQB: PBBSF) (“Peekaboo Beans” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 units (“Units“) at a price of $0.10 per Unit for aggregate gross proceeds of up to approximately $500,000 (the “Private Placement“). The Company intends to use the proceeds from the Private Placement for corporate development and general working capital purposes. Closing of the Private Placement is expected to occur on or before December 21, 2018 (the “Closing Date“).

Each Unit will consist of one (1) common share (each, a “Common Share“) in the capital of the Company and one (1) common share purchase warrant (each, a “Warrant“). Each Warrant will entitle the holder to purchase one Common Share at a price of $0.15 per Common Share until the date which is three (3) years from the Closing Date. The Company has agreed to pay certain eligible finders (each, a “Finder“): (i) a cash fee (which may be payable in Common Shares at a price of $0.10 per Common Share) equal to 8% of the gross proceeds raised by such Finder under the Private Placement; and (ii) issue Warrants to acquire such number of Common Shares equal to 8% of the total number of Units sold by each Finder under the Private Placement.

All securities issued under the Private Placement, including securities issuable on exercise thereof, are subject to a hold period expiring four months and one day from the date hereof.

The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange.

About Peekaboo Beans Inc.

Peekaboo Beans is a children’s apparel brand with a focus on environmentally responsible clothes that are intentionally designed to inspire play. Through an omni-channel approach, Peekaboo Beans engages sellers through social platforms, including Instagram and Facebook, as well as online retailers, to maximize revenue and build brand loyalty. The Company works to promote a playful lifestyle for children by designing comfortable clothes that are built to last.

On behalf of the Board of Directors,
Peekaboo Beans Inc.

Ms. Traci Costa, President and CEO
(604) 279-2326

For more information, please contact the Company at:
BEAN@kincommunications.com
1-866-604-6730

Reader Advisory

This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including statements with respect to the use of proceeds from the Private Placement. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.

Parks! America, Inc. Reports Fiscal 2018 Results

By Parks! America, Inc.

  • F18 sales and adjusted net income, the 2nd highest in Company history
  • Q4 attendance sales increase by 5.6%, to $2,011,074
  • F18 attendance sales decrease by 3.9%, to $5,923,132

PINE MOUNTAIN, GA / ACCESSWIRE / December 14, 2018 / Parks! America, Inc. (OTC PINK: PRKA), today announced the results for its fourth fiscal quarter and fiscal year ended September 30, 2018.

Fourth Quarter 2018 Highlights

Total net sales for the fiscal quarter ended September 30, 2018 were $2,063,345, an increase of $158,872, compared to $1,904,473 for the prior year fiscal quarter ended October 1, 2017. Park attendance based net sales increased by $106,601 or 5.6%, and animal sales increased by $52,271.

The Company reported net income of $551,130 for the fiscal quarter ended September 30, 2018 compared to net income of $435,699 for the prior year fiscal quarter ended October 1, 2017, resulting in an increase of $115,431. Excluding the after-tax impact of the write-off of loan fees associated with our debt refinancing in the fourth quarter of fiscal 2018, the Company generated adjusted net income of $634,901, resulting in an increase of $199,202. The increase in adjusted net income during the fourth quarter of the 2018 fiscal year is primarily attributable to an increase in attendance based net sales, an increase in animal sales, lower compensation and interest expenses, and lower income taxes, partially offset by higher cost of sales, and increased insurance and depreciation expenses.

2018 Fiscal Year Highlights

Total net sales for the 2018 fiscal year were $6,046,758, a decrease of $191,506, compared to $6,238,264 in the 2017 fiscal year. Park attendance based net sales decreased by $240,998 or 3.9%, while animal sales increased by $49,492.

The Company reported net income of $1,011,192 for the 2018 fiscal year compared to net income of $1,260,654 for the 2017 fiscal year, resulting in a decrease of $249,462. Net income for the 2018 fiscal year included a $130,532 charge to write-off loan fees as a result of debt prepayments, 2017 fiscal year included $80,000 of one-time legal settlement income. Excluding the after-tax impact of these items in both years, net income would have decreased $107,323, to $1,103,831 in fiscal 2018. The primary drivers for the $107,323 decrease in adjusted net income during the 2018 fiscal year include a decrease in attendance based net sales, increased insurance, compensation, depreciation and advertising expenses, and higher cost of sales, partially offset by a reduction in legal and interest expenses, and lower income taxes.

“The net sales and adjusted net income we generated in our 2018 fiscal year represent the second highest level of achievement in Company history, only surpassed by the records achieved in our 2017 fiscal year”, commented Dale Van Voorhis, Chairman & CEO. “Considering the extraordinary growth rates in sales and adjusted net income we experienced in our 2017 fiscal year and the above average precipitation level heads winds during the first three quarters of our 2018 fiscal year, overall we are very pleased with our fiscal 2018 results of operations. It bears repeating what I have said before, our management teams continue to perform well and deliver a first class customer experience.”

Balance Sheet and Liquidity

The Company had working capital of $2.54 million as of September 30, 2018 compared to working capital of $3.14 million as of October 1, 2017. The Company utilized approximately $1.55 million of cash on-hand to prepay and refinance its term debt during the 2018 fiscal year.

The Company’s debt to equity ratio was 0.20 to 1.0 as of September 30, 2018, compared to 0.46 to 1.0 as of October 1, 2017.

“The refinancing we completed in July 2018 is a positive reflection on our improved financial position,” noted Mr. Van Voorhis. “We used the proceeds of the 2018 Term Loan, in addition to available cash of approximately $1,250,000, to retire the then outstanding principal balance of our previously outstanding term loan. Additionally, in December 2017, we made a $300,000 prepayment toward our prior term loan. The 2018 Term Loan lowers our term loan interest rate by 200 basis points, to 5.0% per annum, while maintaining a strong cash position to support current operations. Compared to our prior term loan, we project aggregate interest expense savings in the range of $850,000 over the combined seven year term of our loan arrangement with Synovus Bank”.

Management Update

On November 28, 2018, our long time COO and board member, James Meikle, passed away. “Our improved operating performance and the strengthening of our financial position over the past several years is in large measure due to the strong efforts of Mr. Meikle,” commented Mr. Van Voorhis. “We want to reiterate our thanks to Mr. Meikle’s family for his remarkable service, insight and leadership and express our deepest condolences to his family and loved ones.”

“We have a strong management team in place, which we believe is well positioned to continue and improve upon the park operations legacy Mr. Meikle instilled,” continued Mr. Van Voorhis.

The following is a brief introduction for each key individual in the Company’s operations leadership team.

Michael D. (“Mike”) Newman was appointed Vice President of Safari Operations of Parks! America on May 1, 2018. Mr. Newman joined the Company in April 2010, and was the General Manager of Wild Animal Safari – Georgia from February 2011 through April 2018. Under Mr. Newman’s leadership, sales at the Company’s Georgia Park have more than doubled. Prior to joining the Company, Mr. Newman, founded and managed Castle Appraisal Service, a residential and commercial real estate appraisal company. Mr. Newman has held various management roles with retail and banking companies. Mr. Newman also has a background in Biology and Animal Husbandry. He is a member of the Exotic Wildlife Association and the First Baptist Church in LaGrange, Georgia. Mr. Newman received a bachelor’s degree in business management from The University of Georgia.

Kylie A. Deese was appointed General Manager of Wild Animal Safari – Georgia on May 1, 2018. Ms. Deese joined the Company in March 2012 and has subsequently held various positions of increasing responsibility, including promotion to Assistant Manager and Head of Animal Care in March 2015. Since joining the Company, Ms. Deese has endeavored to elevate the standard of animal husbandry, as well as furthering her education and knowledge of our industry. Her formal continuing education experiences include Big Cat husbandry classes, an American Zoological Association Primate Workshop at the Columbus Zoo and Wildlife Safe Capture Certification course. Ms. Deese is also a member of American Association of Zookeepers. Prior to joining the company, Ms. Deese held several customer service and management positions in various companies. Ms. Deese has a bachelor’s of science degree in biology from LaGrange College.

John Gamble was appointed General Manager of Wild Animal Safari – Missouri effective March 1, 2018. Mr. Gamble joined the Company in September 2014 and has subsequently held various positions of increasing responsibility, including promotion to Assistant Manager in October 2017. Prior to joining the Company, Mr. Gamble held various mechanical and maintenance positions, primarily with agricultural based companies.

About Parks! America, Inc.

Parks! America, Inc. (OTC PINK: PRKA), through its wholly owned subsidiaries, owns and operates two regional theme parks – the Wild Animal Safari theme park in Pine Mountain, Georgia, and the Wild Animal Safari theme park located in Strafford, Missouri.

Additional information, including our Form 10-K for the fiscal year ended September 30, 2018, is available on the Company’s website, http://www.animalsafari.com

Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained herein, this news release contains certain “forward-looking statements” within the meaning of U.S. securities laws. You are cautioned to not place undue reliance on these forward-looking statements; actual results or outcomes could differ materially due to factors including, but not limited to: general market conditions, adverse weather, and industry competition. The Company believes that expectations reflected in forward-looking statements are reasonable, however it can give no assurances that such expectations will be realized and actual results could differ materially. The Company assumes no obligation to update any of these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting these forward-looking statements, except as required by applicable law. A further description of these risks, uncertainties and other matters can be found in the Company’s annual report and other reports filed from time to time with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018.

Contact: Todd R. White
Chief Financial Officer
(706) 663-8744
todd.white@animalsafari.com

PARKS! AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
For the Three Months and Year Ended September 30, 2018 and October 1, 2017

For the three months ended For the year ended
September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017
Net
sales
$ 2,011,074 $ 1,904,473 $ 5,923,132 $ 6,164,130
Sale
of animals
52,271 123,626 74,134
Total net sales
2,063,345 1,904,473 6,046,758 6,238,264
Cost
of sales
225,548 167,742 672,777 607,987
Selling, general and administrative
851,102 854,766 3,205,334 3,081,628
Depreciation and amortization
136,797 117,715 425,647 386,065
(Gain) loss on disposal of operating assets, net
6,949 18,054 32,252 17,745
Income from operations
842,949 746,196 1,710,748 2,144,839
Other
income (expense), net
6,412 4,242 20,204 91,373
Write-off of loan fees – prepayment
(118,037 ) (130,532 )
Interest expense
(25,815 ) (49,439 ) (177,828 ) (200,258 )
Income before income taxes
705,509 700,999 1,422,592 2,035,954
Income tax provision
154,379 265,300 411,400 775,300
Net income
$ 551,130 $ 435,699 $ 1,011,192 $ 1,260,654
Income per share – basic and diluted
$ 0.01 $ 0.01 $ 0.01 $ 0.02
Weighted average shares
outstanding (in 000’s) – basic and diluted
74,721 74,671 74,707 74,645

PARKS! AMERICA, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURE – ADJUSTED NET INCOME (1)
For the Three Months and Year Ended September 30, 2018 and October 1, 2017

For the three months ended For the year ended
September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017
Net
Income
$ 551,130 $ 435,699 $ 1,011,192 $ 1,260,654
Write-off of loan fees – prepayment
118,037 130,532
Tax
impact – write-off of loan fees-prepayment
(34,266 ) (37,893 )
Other
income – settlement income
(80,000 )
Tax
impact – settlement income
30,500
Adjusted net income
$ 634,901 $ 435,699 $ 1,103,831 $ 1,211,154

(1) Reconciliation of Non-GAAP Disclosure Item – Adjusted Net Income

Adjusted net income for the three months and year ended September 30, 2018, excludes the write-off of loan fees associated with the prepayment of our 2013 Refinancing term loan. Adjusted net income for the year ended October 1, 2017 excludes income from a legal settlement. Given the one-time nature of these items, management believes excluding them from adjusted net income provides a better indication of year-over-year operating performance.

PARKS! AMERICA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
As of September 30, 2018 and October 1, 2017

September 30, 2018 October 1, 2017
ASSETS
Cash
$ 2,674,260 $ 3,204,043
Inventory
240,004 157,320
Prepaid expenses
131,856 309,626
Total
current assets
3,046,120 3,670,989
Property and equipment, net
6,614,835 6,464,850
Intangible assets, net
1,400 2,200
Deferred tax asset
160,355
Other
assets
12,050 9,199
Total assets
$ 9,674,405 $ 10,307,593
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Accounts payable
$ 92,237 $ 137,717
Other
current liabilities
219,443 281,155
Current portion of long-term debt, net
195,198 111,496
Total
current liabilities
506,878 530,368
Long-term debt, net
1,358,027 2,990,417
Total liabilities
1,864,905 3,520,785
Stockholders’ equity
Common stock
74,721 74,671
Capital in excess of par
4,837,116 4,825,666
Treasury stock
(3,250 ) (3,250 )
Retained earnings
2,900,913 1,889,721
Total stockholders’ equity
7,809,500 6,786,808
Total liabilities and stockholders’ equity
$ 9,674,405 $ 10,307,593

SOURCE: Parks! America, Inc.

ReleaseID: 530593

Cannabis Users Drive High, and Crashes Are on the Rise — CFN Media

Seattle, Washington–(Newsfile Corp. – December 14, 2018) – As cannabis legalization spreads across North America, there is a growing realization of the public safety issues surrounding widespread use of the legalized drug. Even cannabis consumers admit that driving under the influence of marijuana can be dangerous, but in general they do it anyway. Public health officials have launched educational campaigns, but the entrenched idea among cannabis users that the drug is not as dangerous as alcohol is hard to overcome. Add to that the technical difficulties surrounding the testing of THC levels and impairment, and it is easy to see why public health officials see a safety crisis that only promises to grow before practical solutions can be found.

Cannabix Technologies, Inc. (CSE: BLO) (OTC Pink: BLOZF) is advancing a marijuana breathalyzer the company hopes will solve a major part of the current cannabis safety issue. By providing a reliable and convenient roadside testing solution, Cannabix hopes to give law enforcement and employers the tools they currently lack to accurately determine recent marijuana use at the point of care. Combined with continued public education, such a tool could clear up a lot of the grey areas currently surrounding the issue of driving under the influence of legal cannabis and help keep our roads safer.

The Statistics

A study by the Colorado Department of Transportation, released earlier in 2018, found that 69% of marijuana users had driven under the influence in the year prior, with 27% indicating they drove under the influence almost daily. North of the border, the findings are significant as well. Health Canada’s annual Canadian Cannabis Survey found that 39% of marijuana users reported having driven within 2 hours of using the drug, with 43% of those people having driven under the influence in the last 30 days. Clearly, the public safety message is not getting through to a preponderance of cannabis users.

Meanwhile, the Insurance Institute for Highway Safety and Highway Loss Data Institute recently released two studies showing that vehicle crashes rose between 5% and 6% in states that legalized cannabis use, compared to neighboring states that did not legalize. In the linked article, the IIHS notes that “Marijuana’s role in crashes isn’t as clear as the link between alcohol and crashes. Many states don’t include consistent information on driver drug use in crash reports, and policies and procedures for drug testing are inconsistent. More drivers in crashes are tested for alcohol than for drugs.”

In a Las Vegas-area report on the issue, retired Las Vegas lieutenant Randy Sutton lamented the lack of tools to accurately measure marijuana impairment. “Marijuana is a different story,” said Sutton. “Tests to determine someone’s impairment are more guesswork than they are science.” At the same time, Sutton noted the increase of impaired drivers on the road resulting from cannabis legalization.

Tools Needed to Combat the Dangers

Along with a robust educational campaign to change public perceptions and behaviors regarding cannabis use and driving, proper tools are needed to accurately and conveniently identify THC levels in potentially impaired drivers. Mr. Sutton’s lament is a common refrain for law enforcement and public health officials. With invasive, inconsistent, and slow saliva tests being tested, there is a distinct need for the cannabis equivalent of the alcohol breathalyzer.

All of these issues could be alleviated with the introduction of a portable Cannabix Marijuana Breathalyzer. Cannabix is using mass spectrometry (MS) related technology known as field asymmetric waveform ion mobility spectrometry (FAIMS) to ensure accuracy of THC detection from human breath. Cannabix is a well-funded company that has been steadily developing its prototype breathalyzer, advancing its technology to bring the device to market as soon as possible, with research and pilot testing and other milestones ahead.

Cannabis legalization is on the rise and cannabis impaired driving shows no signs of letting up. With current technologies lacking, the introduction of a cannabis breathalyzer could be a game-changer. Stay tuned for further developments.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer

For more information, visit the company’s website at: http://www.cannabixtechnologies.com

Please follow this link to read the full article:

http://www.cannabisfn.com/cannabis-users-d…-are-on-the-rise/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane
206-369-7050
flane@cannabisfn.com